Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

HAYWARD, Calif., May 13, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31st, 2013.

First Quarter 2013 Financial Results:

Loss from operations, which included a non-recurring and non-cash charge of approximately $1.5 million in stock-based compensation, was $6.9 million for the first quarter of 2013, compared to $20.1 million for the first quarter of 2012.  The decrease in loss from operations primarily resulted from a decrease in research and development expenses to $4.9 million from $17.7 million and a decrease in general and administrative expenses from $2.3 million to $2.0 million.  The decrease in research and development expenses in the first quarter of 2013 compared to the first quarter of 2012 was primarily the result of decreased direct and indirect clinical study costs as the Company focuses on the development of blisibimod for systemic lupus erythematosus, or lupus, and IgA nephropathy, an orphan disease.  The Company also experienced lower manufacturing spending as manufacturing of blisibimod for patient dosing in the on-going clinical studies was completed in 2012.  The decrease in general and administrative expenses for the first quarter of 2013 compared to the first quarter of 2012 was primarily due to reduced spending on consulting and professional services and reflects the Company's ongoing cost reduction efforts.

Net loss for the quarter ended March 31, 2013 was $7.6 million, or $0.06 loss per basic and diluted share, compared with loss of $20.9 million, or $0.51 loss per basic and diluted share for the quarter ended March 31, 2012. The decrease in net loss per basic and diluted share in the first quarter of 2013 as compared to the first quarter of 2012 was primarily the result
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... IDM Pharma, Inc.,(the Company) (Nasdaq: IDMI ) ... clinical protocol finalized with the U.S. Food and ... osteosarcoma patients through a compassionate access study., ... increasing number of,requests for compassionate access to L-MTP-PE," ...
... not the Only Way We Suffer - ... Allergies Impact Mood and Self-Perception, KENILWORTH, N.J. and ... about 50,million people in the United States.(1)(2) Yet, according to ... a nuisance: in today,s society allergies get little respect.,As a ...
Cached Medicine Technology:IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 2IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 3IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 4IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 5New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 2New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 3New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 4New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 5New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 6New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 7
(Date:4/15/2014)... mystery and in the process have found a potentially less ... million people a year. The researchers say they now understand the ... in use for more than 50 years even though it ... the microbes it attacks. , A report of the ...
(Date:4/15/2014)... University of California, San Diego School of Medicine have identified ... virus get liver disease and why the virus is able ... The hard-to-kill pathogen, which infects an estimated 200 million people ... dismantling the cell,s innate ability to fight infection. It ...
(Date:4/14/2014)... HIV/AIDS in South Africa may provide insight on how to ... areas of the world, which may have limited access to ... , A report on the global AIDS epidemic published ... pandemic, which has left 12 million children orphaned in Sub-Saharan ...
(Date:4/14/2014)... Alexandria, Va., USA The International and American Associations ... "Rare Bone Diseases and Their Dental, Oral, and Craniofacial ... Andrea B. Burke, Alison M. Boyce, Michael Collins, Brian ... Scott Ramnitz, Martha J. Somerman and J. Timothy Wright ...
(Date:4/14/2014)... that moderate to severe obstructive sleep apnea is independently associated with ... the 20-year follow-up study show that people with moderate to severe ... ratio = 4.2), nearly four times more likely to have a ... cancer (HR = 3.4), and 2.5 times more likely to develop ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2
... But, ... operation, apparently designed to influence a myriad of factors. At least that is what ... best-selling investigative author Daniel Estulin. , ... Walterville, OR/ Bangkok (Vocus) Dec. 21, 2009 -- On Saturday, December ...
... ... http://lcfamerica.org , new organization trying to give the gift of life this holiday season ... cancer remains biggest cancer killer for women and men yet receives least funds for research ... , ...
... , , , WASHINGTON, Dec. 21 ... forward with a bill that imposes a first-ever mandatory abortion tax ... the middle of the night because he knows that the vast ... tax dollars bankrolling insurance plans that cover abortion. A ,yes, vote ...
... 20 More than 40 groups have joined together to ... "Virtual Vigil" starting at 9 pm tonight and wrapping after ... representing millions on the left, right, seniors, tea parties, doctors, ... Senate for laying a $200 billion windfall in mandatory premiums ...
... personal habits more naughty than nice, public health expert says ... really public health enemy No. 1? , Absolutely, says an ... online edition of the BMJ . Jolly Old St. ... Dr. Nathan Grills of Monash University in Melbourne contends. ...
... ... has entered a cooperative partnership with Tennessee-based ECMO Advantage to provide this life-saving medical ... , ... December 20, 2009 -- AirMed International, the leading U.S. air ambulance company, announced today ...
Cached Medicine News:Health News:Author Says Thailand Arms Plane Aimed at Swaying Victor Bout's Extradition 2Health News:Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds 2Health News:Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds 3Health News:Left/Right Healthcare 'Virtual Vigil' Tonight at 9 PM Until Senate Votes; Broad Coalition Says Punishes Some States, Windfall for Insurance Companies 2Health News:Santa Not the Best Role Model for Kids' Health 2Health News:Air Ambulance Company AirMed International Partners with ECMO Advantage for Life-Saving Transports 2Health News:Air Ambulance Company AirMed International Partners with ECMO Advantage for Life-Saving Transports 3
... Flexible Ureteroscope (DUR-D) incorporates many of ... durable, market leading DUR® series flexible ... device utilizing Gyrus ACMIs proprietary, worlds ... Oxide Semi-Conductor (CMOS) distal sensor technology ...
... new ImmunoCard STAT! EHEC is the first one-step ... Shiga Toxin 1 and 2 produced by Enterohemorrhagic ... on McConkey broth overnight enrichment of fecal specimens ... and 100% specificity., The separate result for Toxin ...
Inquire...
... elegant and sophisticated woman, the ... ophthalmic and sunwear styles. Frames ... of shapes and colors, designed ... and complexions. Many styles feature ...
Medicine Products: